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Wilson’s disease
1. An hereditary disease of (dietary) copper 
overload. Fatal if left untreated.
2. Associated with reduced excretion of 
copper in bile.
3. In individuals ranging from age three years 
to over 50 years.
4. Symptoms vary among and within 
families.
5. Treatment for copper overload is life-long.
2012 − centenary of the first 
publication on Wilson’s disease
Samuel Alexander Kinnier Wilson (1878-1937)
Two patients (S.T. & E.P.) with Wilson’s disease 
(pre-symptomatic) described in Brain 1912
S.T. & E.P showing symptoms of 
neurological Wilson’s disease
Clinical manifestations of 
Wilson’s disease
Hepatic
• Persistently elevated serum 
aminotransferases
• Chronic hepatitis
• Cirrhosis (decompensated or 
compensated)
• Fulminant hepatic failure (+/- haemolytic 
anaemia)
Clinical manifestations of 
Wilson’s disease
Neurological
• Tremor
• Choreiform movements
• Parkinsonism or akinetic rigid syndrome
• Gait disturbances
• Dysarthria
• Pseudobulbar palsy
• Rigid dystonia
• Seizures
• Migraine headaches
• Insomnia
Clinical manifestations of Wilson’s 
disease
Ophthalmic
• Kayser-Fleischer rings
• Sunflower cataracts
Psychiatric
• Depression
• Neuroses
• Personality changes
• Psychosis
Lancet, 2007, 369, 397-408
Diagnostic tests for Wilson’s disease
• Opthalmic slit lamp examination for Kayser-
Fleischer rings
• Serum caeruloplasmin test
• 24-hour urine copper test
• Liver biopsy for histology and histochemistry 
and copper quantification
• Genetic testing, haplotype analysis for siblings 
and mutation analysis
• Brain MRI scan
Kayser-Fleischer ring
18-year old female WD patient before chelation therapy
New Engl. J. Med., 2012. 366; e18
Treatment options for Wilson’s 
disease
Reduction in copper overload:
➢ Chelation therapy
➢ Zinc salts
➢ Tetrathiomolybdate
➢ [Liver transplant]
Three copper chelating agents used to 
treat Wilson’s disease
J.N. Cumings,1951 (intramuscular) J.M. Walshe, 1956 (oral)
J.M. Walshe, 1969 (oral)
Other (oral) drugs used to treat 
Wilson’s disease
• Zinc acetate (Wilzin®) or zinc sulfate
(G. Schouwink, 1961)  
• Ammonium tetrathiomolybdate and 
bis(choline) tetrathiomolybdate (TTM)
• TTM used to treat neurological Wilson’s 
disease
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D-Penicillamine
A monodentate, bidentate or a tridentate ligand
Initial dose 1000–1500 mg per day in two to four 
divided doses
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Putative copper-penicillamine 
complex ion
Because: 2RSH  +  2Cu2+ R–S–S–R  +  2Cu+ +  2H+
D-Penicillamine and Cu2+ – aqueous chemistry
• ‘Reductive chelation’
• Form a purple mixed valence cluster 
complex [Cu(II)6Cu(I)8Pen12Cl]
5−
• Relevance to therapeutic action?
Therapeutic action of D-penicillamine
• Induces cupruresis
• Reduces Cu(II) to Cu(I)
• Forms cuprous–penicillamine complexes, 
whose structures are pH dependent
• Does not mobilise Cu(II) bound to albumin; 
acts on other copper pools in vivo
• Its enhanced cupruretic properties are still 
not understood? Particularly in long-term 
use.
D-penicillamine – adverse reactions
10-20% of patients develop immunologically 
induced intolerance to penicillamine
Most serious: 
• Immune-complex nephritis
• Systemic lupus erythematosus (SLE)
• Haemolytic anaemia
• Symptoms mimicking Goodpastures’ 
syndrome
Also, direct chemical toxicity, e.g. pyridoxine 
deficiency and dermatopathy 
J. M. Walshe, The Lancet, March 20, 1982, 643
D-penicillamine – adverse reactions
Neurological worsening:
“No new patient should be prescribed 
penicillamine de novo and sent home. The 
first 2 weeks are critical for that small, but 
unpredictable number of patients who may 
undergo rapid deterioration …”
John Walshe, Curr. Treat. Options Gastroenterol., 2005, 8, 467 
Triethylenetetramine (trientine) 
and its synonyms
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Triethylenetetramine
Triethylenetetramine dihydrochloride
Synonyms:
Trientine dihydrochloride, BAN, INN
Trientine hydrochloride, USAN
Trien; TRIEN; TETA; Cuprid (Merck); Syprine (Merck); 
Metalite (Tsumura); Laszarin (Protemix); MK 681; PX 811019   (Protemix)
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“Drugs for Rare Diseases”
“…Recently the hospital pharmacy 
[Addenbrooke’s] agreed to take over the 
purification of trien.2HCl [trientine]…In my view this 
do-it-yourself exercise has continued quite long 
enough and should be placed on a sound 
commercial basis.” 
Dr John Walshe, Brit. Med. J., 20th September 1975,
p 701. Reported in New Scientist, 25th September,
1975
Production of trientine dihydrochloride
❑ From commercial (technical grade) triethylenetetramine
❑ A very cheap industrial chemical (£20/kilogram: Aldrich 
catalogue)
❑ Trientine – UK price (1 x 300 mg capsule) ca. £30 
❑ Trientine – USA price (1 x 250 mg capsule) ca. £140
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Trientine
Dihydrochloride
Tetrahydrochloride
A quadridentate ligand
Coordination of trientine with cupric ions
Cu2+ + trien  [Cu(trien)]2+
Stability constant (KML)
KML = [Cu(trien)]
2+/[Cu2+][trien] = 1020.1 mol−1 dm3
log10 KML = 20.1 (a typical experimental value).
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Action of trientine
• Induces cupruresis
• Chelates copper in the intestinal tract, 
reducing copper absorption in vivo
• Removes Cu(II) from Cu(II)–albumin to 
form [Cu(trien)]2+
Administration of trientine.2HCl
• Initial dose of trientine 750–1500 mg/day 
in two or three divided doses
• Given on an empty stomach – 1 hour 
before or 2 hours after a meal 
A patient showing improvement in the symptoms of 
neurological Wilson’s disease following treatment with 
trientine
Harders, H.; Cohnen, E., Proc. R. Soc. Med., 1977, 70 
Suppl. 3, 10
Trientine – adverse effects
• Sideroblastic anemia (RARE)
• Lupus-like reactions (from residual D-pen 
treatment?) (RARE)
• Haemorrhagic gastritis, loss of taste, and skin 
changes (rashes) (RARE)
• Trientine-induced colitis (RARE)
• Neurological deterioration during trientine
treatment has been reported
Trientine tetrahydrochloride 
(Cuprior)
• Manufactured in tablet form in France
• EMA approval (2017) for treating Wilson’s 
disease in EU
• Tablets stable at room temperature
• Claimed to be effective at a lower 
equivalent dose than the dihydrochloride
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Zinc salts
• Zn2+ induces intestinal metallothionein, 
which preferentially binds to copper 
within the duodenal enterocyte
• Copper absorption into the circulation is 
reduced, and copper is lost when the 
enterocyte is shed during normal cell 
turnover
• Without normal absorption but with 
continuing copper losses there is a 
negative copper balance
Treatment of Wilson’s disease with 
zinc salts
• Recommended as a maintenance therapy 
after initial ‘decoppering’
• Used in asymptomatic or presymptomatic 
family members of individuals with 
Wilson’s disease
• Dyspepsia a side-effect
Zinc acetate crystals
Tetrathiomolybdate (TTM) MoS4
2–
• Ammonium tetrathiomolybdate (NH4)MoS4
(J.M.Walshe, 1984; G.J. Brewer, 1991)
• Bis(choline) tetrathiomolybdate 
Code Name WTX101 (Wilson Therapeutics)
Tetrathiomolybdate (TTM) MoS4
2–
TTM interacts with Cu(I) to form copper–molybdenum–
sulfur clusters:
Action of TTM
• Decreases absorption of dietary copper
• Augments Cu excretion into bile
• WTX101 undergoing clinical trials in the UK
• Phase 2 published; Phase 3 in progress
The Lancet Gastroenterology & Hepatology, 2017. 2, 869-876
Wilson’s disease – genetic aspects
• Characterized by decreased biliary excretion of copper and 
reduced incorporation of copper into apoceruloplasmin
• Caused by homozygous or compound heterozygous 
mutations in the ATP7B gene, which encodes a copper-
transporting P-type ATPase
• Over 500 mutations in the ATP7B gene have been reported 
• Accepted prevalence of  WD of 1:30 000 questioned by 
Sheffield Diagnostic Genetics Service
• Possibility of many undiagnosed WD cases in the UK
Brain, 2013, 136, 1476-1487
Wilson’s Disease Support Group – UK 
(WDSG – UK)
• Provides support for patients, families, and 
friends
• Raises funds and sponsors research into 
Wilson’s disease
• Annual newsletter
• WDSG − UK website & Facebook page
UK WD patients’ concerns
• Awareness of WD by health professionals; delayed 
initial diagnosis; unrecognised cases
• Access to WD specialists — WD specialists located in 
centres of excellence in the UK; a holistic approach to 
treatment
• More attention to post-diagnosis ‘quality of life’ issues:
- effect of medication on skin;
- problems with joints;
- appreciation of residual psychiatric problems
• Issues with prescription charges — simplification of 
any available reductions in prescription costs 
Wilson’s Disease Support Group – UK 
Meeting, King’s College Cambridge, 
2006
Dr John Walshe and his first WD patient from 
1955 (2017 WDSG-UK Annual Meeting)
BASL Wilson’s Disease Special 
Interest Group 
• WD Special Interest Group comprises UK 
clinical and laboratory specialists
• Aims are to foster collaboration for clinical 
and scientific research
• Provide a forum to discuss and disseminate 
best practice
• Act as a stimulus towards Centres of 
Excellence for Wilson’s disease

